Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

miR-133a function in the pathogenesis of dedifferentiated liposarcoma.

Yu PY, Lopez G, Braggio D, Koller D, Bill KLJ, Prudner BC, Zewdu A, Chen JL, Iwenofu OH, Lev D, Strohecker AM, Fenger JM, Pollock RE, Guttridge DC.

Cancer Cell Int. 2018 Jun 26;18:89. doi: 10.1186/s12935-018-0583-2. eCollection 2018.

2.

Exosome-Derived miR-25-3p and miR-92a-3p Stimulate Liposarcoma Progression.

Casadei L, Calore F, Creighton CJ, Guescini M, Batte K, Iwenofu OH, Zewdu A, Braggio DA, Bill KL, Fadda P, Lovat F, Lopez G, Gasparini P, Chen JL, Kladney RD, Leone G, Lev D, Croce CM, Pollock RE.

Cancer Res. 2017 Jul 15;77(14):3846-3856. doi: 10.1158/0008-5472.CAN-16-2984. Epub 2017 Jun 6.

3.

Liposarcoma: molecular targets and therapeutic implications.

Bill KL, Casadei L, Prudner BC, Iwenofu H, Strohecker AM, Pollock RE.

Cell Mol Life Sci. 2016 Oct;73(19):3711-8. doi: 10.1007/s00018-016-2266-2. Epub 2016 May 12. Review.

PMID:
27173057
4.

SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma.

Bill KL, Garnett J, Meaux I, Ma X, Creighton CJ, Bolshakov S, Barriere C, Debussche L, Lazar AJ, Prudner BC, Casadei L, Braggio D, Lopez G, Zewdu A, Bid H, Lev D, Pollock RE.

Clin Cancer Res. 2016 Mar 1;22(5):1150-60. doi: 10.1158/1078-0432.CCR-15-1522. Epub 2015 Oct 16.

5.

HDAC Inhibition for the Treatment of Epithelioid Sarcoma: Novel Cross Talk Between Epigenetic Components.

Lopez G, Song Y, Lam R, Ruder D, Creighton CJ, Bid HK, Bill KL, Bolshakov S, Zhang X, Lev D, Pollock RE.

Mol Cancer Res. 2016 Jan;14(1):35-43. doi: 10.1158/1541-7786.MCR-15-0295. Epub 2015 Sep 22.

6.

HDAC8, A Potential Therapeutic Target for the Treatment of Malignant Peripheral Nerve Sheath Tumors (MPNST).

Lopez G, Bill KL, Bid HK, Braggio D, Constantino D, Prudner B, Zewdu A, Batte K, Lev D, Pollock RE.

PLoS One. 2015 Jul 22;10(7):e0133302. doi: 10.1371/journal.pone.0133302. eCollection 2015.

7.

The hepatocyte growth factor receptor as a potential therapeutic target for dedifferentiated liposarcoma.

Bill KL, Garnett J, Ma X, May CD, Bolshakov S, Lazar AJ, Lev DC, Pollock RE.

Lab Invest. 2015 Aug;95(8):951-61. doi: 10.1038/labinvest.2015.62. Epub 2015 Jun 1.

Supplemental Content

Support Center